227 results on '"Branagan, A. R."'
Search Results
2. Elotuzumab in combination with pomalidomide, bortezomib, and dexamethasone in relapsed and refractory multiple myeloma
3. Ibrutinib and venetoclax as primary therapy in symptomatic, treatment-naïve Waldenström macroglobulinemia
4. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
5. Response and survival predictors in a cohort of 319 patients with Waldenström macroglobulinemia treated with ibrutinib monotherapy
6. Effect of granulocyte colony-stimulating factor on toxicities after CAR T cell therapy for lymphoma and myeloma
7. Tandem high-dose influenza vaccination is associated with more durable serologic immunity in patients with plasma cell dyscrasias
8. Identification of robust predictors for ibrutinib response by multi-omics in MYD88 mutated Waldenstrom Macroglobulinemia
9. Lifestyle considerations in multiple myeloma
10. Identification of robust predictors for ibrutinib response by multiomics in MYD88-mutated Waldenström macroglobulinemia
11. Report of consensus panel 5 from the 11th international workshop on Waldenstrom's macroglobulinemia on COVID-19 prophylaxis and management
12. The ERK1/2 Regulator WNK2 Shows Novel Alternative Splicing Aberrations That Support Tumor Growth in MYD88 Mutated Waldenström's Macroglobulinemia
13. Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom's Macroglobulinemia
14. Clinical Effectiveness and Long-Term Serologic Responses of COVID-19 Vaccination in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
15. A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
16. Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
17. IgM-Related Immunoglobulin Light Chain (AL) Amyloidosis
18. Skin Punch Biopsy Findings in Patients with IgM MGUS and Waldenström Macroglobulinemia Presenting with Peripheral Neuropathy
19. Multi-Omic Analysis of 253 Untreated Patients with Waldenström's Macroglobulinemia Reveals Clinically and Genomically Distinct Disease Subtypes and a Model for Disease Progression
20. Quality of life, psychological distress, and prognostic perceptions in caregivers of patients with multiple myeloma
21. A new role for the SRC family kinase HCK as a driver of SYK activation in MYD88 mutated lymphomas
22. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia
23. Long-term outcomes to fludarabine and rituximab in Waldenström macroglobulinemia
24. Infectious Complications in Patients Treated with Idecabtagene Vicleucel for Relapsed and Refractory Multiple Myeloma
25. A Phase II Study of Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, and Isatuximab in Newly Diagnosed, Transplant-Eligible Multiple Myeloma
26. COVID-19 Vaccine Responsiveness in Patients with Multiple Myeloma and Waldenström Macroglobulinemia
27. Preliminary Clinical Response Data from a Phase 1b Study of Mavorixafor in Combination with Ibrutinib in Patients with Waldenström's Macroglobulinemia with MYD88 and CXCR4 Mutations
28. Quality of Life, Psychological Distress, and Prognostic Awareness in Patients with Multiple Myeloma
29. Quality of Life, Psychological Distress, and Prognostic Awareness in Caregivers of Patients with Multiple Myeloma
30. Pirtobrutinib (LOXO-305) Is Active and Overcomes ERK Related Pro-Survival Signaling in Ibrutinib Resistant, BTK Cys481 Mutant Expressing WM and ABC DLBCL Lymphoma Cells Driven By Activating MYD88 Mutations
31. Real-World Observations and Practical Considerations of Subcutaneous Daratumumab Administration in Multiple Myeloma
32. Molecular Features and Clinical Outcomes of Extramedullary Plasmacytomas
33. CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia
34. Thalidomide and rituximab in Waldenstrom macroglobulinemia
35. Diagnostic Next-generation Sequencing Frequently Fails to Detect MYD88L265P in Waldenström Macroglobulinemia
36. Use of Cilta-Cel CAR T Cells Following Previous Use of a BCMA-Directed CAR T-Cell Product in Heavily Treated Patients with Relapsed/Refractory Multiple Myeloma: A Single Institution Case Series
37. Ibrutinib and Venetoclax in Symptomatic, Treatment-Naive Patients with Waldenström Macroglobulinemia
38. A Phase II Study of Isatuximab, Once Weekly Carfilzomib, Lenalidomide, Dexamethasone, in Newly Diagnosed, Transplant-Eligible Multiple Myeloma (The SKylaRk Trial)
39. Prospective Study of Acalabrutinib with Rituximab in Patients with Symptomatic Anti-MAG Mediated IgM Peripheral Neuropathy
40. Quantitative MYD88 L265P Analysis Represents a Powerful Tool for Assessing Disease Response and Evaluating Clinical Trial Performance in Waldenstrom's Macroglobulinemia
41. Aberrant Expression of Spliced WNK2 Is an Early Event in MYD88 Mutated WM That Activates ERK1/2 and Supports Tumor Growth
42. Establishment of BCWM.1 cell line for Waldenström's macroglobulinemia with productive in vivo engraftment in SCID-hu mice
43. Natural history of Waldenström macroglobulinemia following acquired resistance to ibrutinib monotherapy
44. Cell‐free DNA analysis for detection ofMYD88 L265PandCXCR4 S338Xmutations in W aldenström macroglobulinemia
45. Update on treatment recommendations from the Third International Workshop on Waldenström's Macroglobulinemia
46. Extending Dosing Intervals of Denosumab As a Maintenance Strategy in Multiple Myeloma: A Real-World Experience at a Large Academic Cancer Center
47. Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID‐19 Pandemic
48. Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia
49. Consensus statement on the management of Waldenström macroglobulinemia patients during the COVID-19 pandemic
50. Hepatitis C Viral Infection Is Not Associated With Waldenströmʼs Macroglobulinemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.